Insight

Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward

cbtn.org

Dec 10, 2023, 18:01

Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward

Giselle Sholler, Division Chief Pediatric Hematology/Oncology/BMT at Penn State Health Children’s Hospital, shared on LinkedIn:

“Our research that led to the FDA-ODAC 70% approval for moving DFMO forward had been published in the Journal of Clinical Oncology!! I am so proud of our Beat Childhood Cancer Research Consortium at Penn State College of Medicine in collaboration with US WorldMeds for this article. We are hopeful and optimistic that this research will successfully navigate the drug through the approval process!”

For the article click here.
Source: Giselle Sholler/LinkedIn

article Beat Childhood Cancer Research Consortium cancer DFMO FDA Giselle Sholler OncoDaily Oncology Penn State College of Medicine Research US WorldMeds

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage